menu
    • menu
    [{"orgOrder":0,"company":"Ingenza","sponsor":"Amplifica","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Ingenza","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Ingenza \/ Amplifica","highestDevelopmentStatusID":"1","companyTruncated":"Ingenza \/ Amplifica"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Proxalutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"1","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"WuXi Biologics \/ Almirall","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Almirall"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"RODAN & FIELDS LLC","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Difluorocyclohexyloxyphenol","moa":"hTyr","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ RODAN & FIELDS LLC","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ RODAN & FIELDS LLC"},{"orgOrder":0,"company":"CollPlant","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"rhCollagen","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"CollPlant","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CollPlant \/ Allergan Aesthetics","highestDevelopmentStatusID":"1","companyTruncated":"CollPlant \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Avra","sponsor":"Springs Rejuvenation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Avra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avra \/ Springs Rejuvenation","highestDevelopmentStatusID":"1","companyTruncated":"Avra \/ Springs Rejuvenation"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revance Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Viatris","highestDevelopmentStatusID":"1","companyTruncated":"Revance Therapeutics \/ Viatris"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Difluorocyclohexyloxyphenol","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Inapplicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Difluorocyclohexyloxyphenol","moa":"Tyrosinase activity","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Undisclosed"},{"orgOrder":0,"company":"JT Pharmaceuticals","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"JT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"JT Pharmaceuticals \/ Titan Pharmaceuticals Inc","highestDevelopmentStatusID":"1","companyTruncated":"JT Pharmaceuticals \/ Titan Pharmaceuticals Inc"},{"orgOrder":0,"company":"Max Planck","sponsor":"Scinai Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Max Planck","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Max Planck \/ Scinai Immunotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Max Planck \/ Scinai Immunotherapeutics"},{"orgOrder":0,"company":"Pressure BioSciences","sponsor":"QVC Skincare","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Vitamin A","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Pressure BioSciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Pressure BioSciences \/ QVC Skincare","highestDevelopmentStatusID":"1","companyTruncated":"Pressure BioSciences \/ QVC Skincare"},{"orgOrder":0,"company":"Topix Skin Health","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"ProteXidine","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Topix Skin Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Topix Skin Health \/ University of Minnesota","highestDevelopmentStatusID":"1","companyTruncated":"Topix Skin Health \/ University of Minnesota"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Crescita Therapeutics \/ Inapplicable"}]

    Find Novel Dermatology Drugs in Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Topix Skin Health

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Topix Skin Health

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ProteXidine

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : University of Minnesota

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            TOPIX Partners with University of Minnesota for ProteXidine Molecule Development

                            Details : The partnership aims to develop a proprietary molecule ProteXidine, a biomimetic decoy molecule that enhances the skin's innate ability to manage UV induced damage and inhibit the production of ROS.

                            Product Name : ProteXidine

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 06, 2024

                            Lead Product(s) : ProteXidine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : University of Minnesota

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Max Planck

                            Country arrow
                            German Wound Congress
                            Not Confirmed

                            Max Planck

                            Country arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Scinai Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biondvax Signs Exclusive License Agreement for Development and Commercialization of a Novel Anti-IL-17 Antibod...

                            Details : The agreement aims to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) as treatments for all potential indications, starting with psoriasis and psoriatic arthritis.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            May 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Scinai Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ingenza

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Ingenza

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Amplifica

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Ingenza Collaborates with Amplifica to Advance Novel Alopecia Treatments

                            Details : Amplifica has partnered with Ingenza to advance the development of its signalling molecules, which stimulate dormant hair follicle stem cells and result in the active regrowth of hairs, from proof of concept through toxicology and clinical trials.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Amplifica

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pressure BioSciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Pressure BioSciences

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitamin A

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : QVC Skincare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Pressure BioSciences Partnership with QVC Skincare Leader Dr. Denese SkinScience Yields Unprecedented Effectiv...

                            Details : Retinol (and its derivative retinoate) is a form of Vitamin A used in multiple skincare products, such as lotions, creams, and serums. It has excellent antioxidant properties and is regarded as the number one anti-aging, wrinkle fighting, skin tightening...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 12, 2022

                            Lead Product(s) : Vitamin A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : QVC Skincare

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OliX Pharmaceutical

                            South Korea arrow
                            German Wound Congress
                            Not Confirmed

                            OliX Pharmaceutical

                            South Korea arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLX104C

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OliX Pharmaceuticals to Present at SMi 13th Annual RNA Therapeutics Conference

                            Details : OliX, will deliver a focused company’s proprietary asymmetric siRNA technology and pipeline programs, including OLX104C for hair loss, OLX301A for wet/dry age-related macular degeneration, OLX702A for non-alcoholic steatohepatitis, and OLX703A for hepa...

                            Product Name : OLX104C

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 02, 2022

                            Lead Product(s) : OLX104C

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sirona Biochem Corp

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Sirona Biochem Corp

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difluorocyclohexyloxyphenol

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Allergan Aesthetics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

                            Details : Under Licensing agreement with Sirona, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 (Difluorocyclohexyloxyphenol) and...

                            Product Name : TFC-1067

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 13, 2022

                            Lead Product(s) : Difluorocyclohexyloxyphenol

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Allergan Aesthetics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sirona Biochem Corp

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Sirona Biochem Corp

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difluorocyclohexyloxyphenol

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : RODAN & FIELDS LLC

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields

                            Details : Under the terms of the agreement, Sirona will manufacture and supply TFC-1067 (difluorocyclohexyloxyphenol), a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorpo...

                            Product Name : TFC-1067

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 16, 2022

                            Lead Product(s) : Difluorocyclohexyloxyphenol

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : RODAN & FIELDS LLC

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Avra

                            Country arrow
                            German Wound Congress
                            Not Confirmed

                            Avra

                            Country arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Springs Rejuvenation

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company

                            Details : The combined entity will focus on stem cell therapy, facial rejuvenation, hair rejuvenation, non-surgical hair restoration, protein rich plasma (PRP) injections, and anti-aging treatments.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 20, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Springs Rejuvenation

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CollPlant

                            Israel arrow
                            German Wound Congress
                            Not Confirmed

                            CollPlant

                            Israel arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhCollagen

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Allergan Aesthetics

                            Deal Size : $103.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CollPlant Inks Global Commercialization Deal with Allergan Aesthetics for rhCollagen in Dermal and Soft Tissue...

                            Details : CollPlant has granted Allergan Aesthetics worldwide exclusivity to use its plant-derived recombinant human collagen (rhCollagen) in combination with Allergan Aesthetics' proprietary technologies, for the production and commercialization of dermal and sof...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $14.0 million

                            August 02, 2021

                            Lead Product(s) : rhCollagen

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Allergan Aesthetics

                            Deal Size : $103.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lipidor AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed

                            Lipidor AB

                            Sweden arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Cannassure Therapeutics

                            Deal Size : $0.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lipidor and Cannassure Enter Exclusive Licensing Agreement Regarding Topical Medical Cannabis Products Based o...

                            Details : Under the agreement, Cannassure has the exclusive right to use Lipidor’s proprietary drug delivery technology AKVANO®in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 18, 2021

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Cannassure Therapeutics

                            Deal Size : $0.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth